Where Cabaletta Bio Stands With Analysts
Portfolio Pulse from Benzinga Insights
Cabaletta Bio (NASDAQ:CABA) has received positive ratings from analysts in the last quarter, with 5 bullish and 3 somewhat bullish ratings, and no negative ratings. The average 12-month price target for CABA is $29.5, which is an 88.26% increase from the previous target of $15.67. The high target is $40.00 and the low target is $17.00.
November 10, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cabaletta Bio has received overwhelmingly positive ratings from analysts, with a significant increase in the average price target to $29.5, suggesting a strong bullish sentiment.
The unanimous positive ratings and the substantial increase in the average price target indicate a strong consensus among analysts about the stock's potential. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100